BMC Cancer最新文献

{"title":"Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.","authors":"Jia Chen, Xue Zhang, Guanyi Zhang, Fan Zhu, Weiwei Liu","doi":"10.1186/s12885-025-13659-2","DOIUrl":"10.1186/s12885-025-13659-2","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the potential of serum exosomal miRNAs as novel biomarkers for pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>Serum exosomal miRNAs were screened and verified by microarray analysis and quantitative real-time PCR (qRT-PCR) in patients with PDAC and healthy controls. The correlation between the clinical characteristics of PDAC and candidate exosomal miRNAs was analyzed, and the diagnostic performance of the candidate biomarkers was evaluated.</p><p><strong>Results: </strong>Serum exosomal miR-7977 and miR-451a were significantly upregulated in PDAC patients compared with healthy controls, and the levels of miR-7977 and miR-451a in serum exosomes were closely associated with the clinical stage and metastasis of PDAC patients. The area under curve (AUC) values of serum exosomal miR-7977 and miR-451a for PDAC were 0.825 and 0.804 in the training set and 0.796 and 0.830 in the validation set, respectively. A biomarker panel consisting of these two miRNAs resulted in a diagnostic power with an AUC of 0.901 in the training set and 0.918 in the validation set.</p><p><strong>Conclusions: </strong>Serum exosomal miR-7977 and miR-451a might be diagnostic biomarkers for PDAC. These two miRNAs, when combined, exhibit optimal diagnostic performance.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"295"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT-based intratumoral and peritumoral radiomics combining ensemble learning for prognosis prediction in hepatocellular carcinoma: a multi-center study.","authors":"Chunxiao Sui, Kun Chen, Enci Ding, Rui Tan, Yue Li, Jie Shen, Wengui Xu, Xiaofeng Li","doi":"10.1186/s12885-025-13649-4","DOIUrl":"10.1186/s12885-025-13649-4","url":null,"abstract":"<p><strong>Background: </strong>Radiomic models combining intratumoral with peritumoral features are potentially beneficial to enhance the predictive performance. This study aimed to identify the optimal ¹⁸F-FDG PET/CT-derived radiomic models for prediction of prognosis in hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A total of 135 HCC patients from two institutions were retrospectively included. Four peritumoral regions were defined by dilating tumor region with thicknesses of 2 mm, 4 mm, 6 mm, and 8 mm, respectively. Based on segmentation of intratumoral, peritumoral and integrated volume of interest (VOI), corresponding radiomic features were extracted respectively. After feature selection, a total of 15 intratumoral radiomic models were constructed based on five ensemble learning algorithms and radiomic features from three image modalities. Then, the optimal combination of ensemble learning algorithms and image modality in the intratumoral models was selected to develop subsequent peritumoral radiomic models and integrated radiomic models. Finally, a nomogram was developed incorporating the optimal radiomic model with clinical independent predictors to achieve an intuitive representation of the prediction model.</p><p><strong>Results: </strong>Among the intratumoral radiomic models, the one which combined PET/CT-based radiomic features with SVM classifier outperformed other models. With the addition of peritumoral information, the integrated model based on an integration of intratumoral and 2 mm-peritumoral VOI, was finally approved as the optimal radiomic model with a mean AUC of 0.831 in the internal validation, and a highest AUC of 0.839 (95%CI:0.718-0.960) in the external test. Furthermore, a nomogram incorporating the optimal radiomic model with HBV infection and TNM status, was able to predict the prognosis for HCC with an AUC of 0.889 (95%CI: 0.799-0.979).</p><p><strong>Conclusions: </strong>The integrated intratumoral and peritumoral radiomic model, especially for a 2 mm peritumoral region, was verified as the optimal radiomic model to predict the overall survival of HCC. Furthermore, combination of integrated radiomic model with significant clinical parameter contributed to further enhance the prediction efficacy.</p><p><strong>Trial registration: </strong>This study was a retrospective study, so it was free from registration.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"300"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic outcomes of thermal ablation versus repeated hepatic resection for recurrent hepatocellular carcinoma by using propensity score analysis: a multicenter real-world study.","authors":"Ke Zhang, Wenbo Wang, Lei Mu, Liting Xie, Mengmeng Li, Wei Yang, Tianan Jiang","doi":"10.1186/s12885-025-13660-9","DOIUrl":"10.1186/s12885-025-13660-9","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic value of thermal ablation (TA) versus repeat hepatic resection (RHR) for recurrent hepatocellular carcinoma (rHCC) after initial hepatic resection is uncertain. This study aimed to investigate the prognosis of TA and RHR.</p><p><strong>Materials and methods: </strong>In this multicenter real-world retrospective study, 473 patients were enrolled between January 2015 and August 2023, with 340 in the TA group and 133 in the RHR group. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were employed to reduce selection bias. Local tumor progression (LTP), recurrence-free survival (RFS), and post-recurrence survival (PRS) were compared before and after PSM and IPTW.</p><p><strong>Results: </strong>A total of 473 patients (231 aged ≥ 60 years; 393 men) were evaluated. LTP, RFS, and PRS rates did not differ significantly between groups before (P = 0.940, P = 0.180, and P = 0.700) and after matching (P = 0.420, P = 0.680, and P = 0.810) and weighting (P = 0.940, P = 0.180, and P = 0.700). Multivariable Cox analysis identified tumor number (HR: 2.28; P < 0.001) and PLT (HR: 0.73; P = 0.038) as independent prognostic factors for RFS in the entire rHCC cohort. And tumor location, size, number, ascites, AST, and AFP (HR: 0.55-2.18; P = 0.004-0.046) were independent prognostic factors for PRS. Subgroup analysis showed both TA and RHR were effective treatments for rHCC, regardless of tumor size, number, subcapsular, or perivascular lesions.</p><p><strong>Conclusions: </strong>The cumulative LTP, RFS, and PRS were not significantly different between TA and RHR for rHCC within the Milan criteria. TA may be a viable curative option for early-stage rHCC patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"303"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.","authors":"Luzhe Yan, Haisu Liang, Tiezheng Qi, Dingshan Deng, Jinhui Liu, Yunbo He, Jinbo Chen, Benyi Fan, Yiyan Yao, Kun Wang, Xiongbing Zu, Minfeng Chen, Yuanqing Dai, Jiao Hu","doi":"10.1186/s12885-025-13698-9","DOIUrl":"10.1186/s12885-025-13698-9","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BLCA) is notably associated with advanced age, characterized by its high incidence and mortality among the elderly. Despite promising advancements in models that amalgamate molecular subtypes with treatment and prognostic outcomes, the considerable heterogeneity in BLCA poses challenges to their universal applicability. Consequently, there is an urgent need to develop a new molecular subtyping system focusing on a critical clinical feature of BLCA: senescence.</p><p><strong>Methods: </strong>Utilizing unsupervised clustering on the Cancer Genome Atlas Program (TCGA)-BLCA cohort, we crafted a senescence-associated molecular classification and precision quantification system (Senescore). This method underwent systematic validation against established molecular subtypes, treatment strategies, clinical outcomes, the immune tumor microenvironment (TME), relevance to immune checkpoints, and identification of potential therapeutic targets.</p><p><strong>Results: </strong>External validations were conducted using the Xiangya cohort, IMvigor210 cohort, and meta-cohort, with multiplex immunofluorescence confirming the correlation between Senescore, immune infiltration, and cellular senescence. Notably, patients categorized within higher Senescore group were predisposed to the basal subtype, showcased augmented immune infiltration, harbored elevated driver gene mutations, and exhibited increased senescence-associated secretory phenotype (SASP) factors expression in the transcriptome. Despite poorer prognoses, these patients revealed greater responsiveness to immunotherapy and neoadjuvant chemotherapy.</p><p><strong>Conclusions: </strong>Our molecular subtyping and Senescore, informed by age-related clinical features, accurately depict age-associated biological traits and its clinical application potential in BLCA. Moreover, this personalized assessment framework is poised to identify senolysis targets unique to BLCA, furthering the integration of aging research into therapeutic strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"297"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-hospital cardiac arrest event after cancer diagnosis: a korean metropolitan cohort study.","authors":"Sun Young Lee, Jeong Ho Park, Yoonjic Kim, Jungah Lee, Young Sun Ro, Kyoung Jun Song, Sang Do Shin","doi":"10.1186/s12885-025-13717-9","DOIUrl":"10.1186/s12885-025-13717-9","url":null,"abstract":"<p><strong>Background: </strong>The importance of assessing out-of-hospital cardiac arrest (OHCA) risk in cancer patients is increasing as cancer incidence rises in aging populations.</p><p><strong>Objective: </strong>This study aimed to investigate the association between newly diagnosed cancer and OHCA risk using a metropolitan cohort from South Korea.</p><p><strong>Methods: </strong>A population-based retrospective cohort study was conducted, linking the nationwide OHCA registry with the National Health Information Database. The study included adults aged 40 years or older, residing in Seoul between 2015 and 2018, with no history of cancer or OHCA. The main exposure was cancer development. The primary outcome was the occurrence of OHCA with medical cause. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a cause-specific hazard model considering death as a competing risk. Analyses stratified by age group and cancer type were also conducted.</p><p><strong>Results: </strong>During a follow-up period of up to 4 years for 5,450,438 individuals, 174,785 participants developed cancer. The incidence rates of OHCA per 100,000 person-years were 54.0 in non-cancer and 145.0 in cancer groups, respectively. The aHR (95% CI) for OHCA associated with cancer development was 3.18 (2.97-3.41). The aHR (95% CI) for OHCA was highest in the 40-49 years of age group (7.52 [5.52-10.25]), followed by 50-59 years old (6.66 [5.56-7.97]) compared to older age groups. By cancer type, pancreatic, lung, biliary tract, and liver cancer were associated with a significantly increased risk of OHCA.</p><p><strong>Conclusion: </strong>We found an association between newly diagnosed cancer and the occurrence of OHCA. Our findings underscore the importance of tailored risk assessments and proactive care planning for patients with cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"301"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global trends and risk factors of laryngeal cancer: a systematic analysis for the Global Burden of Disease Study (1990-2021).","authors":"Tianjiao Zhou, Xiaoting Wang, Qingchao Zhu, Enhui Zhou, Jingyu Zhang, Fan Song, Chen Xu, Ying Shen, Jianyin Zou, Huaming Zhu, Kaiming Su, Wen Lu, Hongliang Yi, Weijun Huang","doi":"10.1186/s12885-025-13700-4","DOIUrl":"10.1186/s12885-025-13700-4","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to explore the epidemiological trends of laryngeal cancer (LC) using the 2021 Global Burden of Disease (GBD) data.</p><p><strong>Methods: </strong>We analyzed the global LC incidence, deaths, disability-adjusted life years (DALYs), and risk factors from 1990 to 2021. We evaluated trends using the annual percentage change (EAPC) and examined variations and associations in LC burden across regions, sociodemographic index (SDI) categories, and age groups.</p><p><strong>Results: </strong>In 2021, the global age-standardized incidence rate (ASIR) for LC was 2.293 (95% UI: 2.133-2.466), the age-standardized death rate (ASDR) was 1.35 (1.259-1.449), and the age-standardized DALYs rate was 35.803 (33.294-38.538). The EAPCs for ASIR, ASDR, and age-standardized DALYs were -1.089, -1.659, and -1.816, respectively. The ASIR was positively correlated with the SDI (R = 0.32, P < 0.05). The Caribbean had the highest ASDR (2.69) and second-highest EAPC of ASDR (-0.151). Tobacco accounted for 66.46% of global LC deaths, with a decreasing trend over the last 30 years (R = -1, P < 0.05). Conversely, occupational exposure among females showed an increasing trend (R = 0.61, P < 0.05). The reduction in death rate for the 80-89 years age group was nearly twice as high in the high SDI regions as in the low SDI regions (21.89% vs. 11.92%).</p><p><strong>Conclusions: </strong>From 1990 to 2021, global LC incidence, deaths, and DALYs decreased, although regional disparities persisted. Death rates remain high in economically disadvantaged regions, especially among the elderly and females with occupational risk. Continued efforts to control tobacco use, develop equitable screening programs, and enhance occupational safety are crucial for addressing global disparities in LC outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"296"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A preoperative pathological staging prediction model for esophageal cancer based on CT radiomics.","authors":"Haojun Li, Shuoming Liang, Mengxuan Cui, Weiqiu Jin, Xiaofeng Jiang, Simiao Lu, Jicheng Xiong, Hainan Chen, Ziwei Wang, Guotai Wang, Jiming Xu, Linfeng Li, Yao Wang, Haomiao Qing, Yongtao Han, Xuefeng Leng","doi":"10.1186/s12885-025-13697-w","DOIUrl":"10.1186/s12885-025-13697-w","url":null,"abstract":"<p><strong>Background: </strong>Accurate and comprehensive preoperative staging is one of the most important prognostic factors for the management of esophageal cancer (EC). We aimed to develop and validate predictive models using radiomics from preoperative contrast-enhanced Computed Tomography (CT) images to assess pathological staging in EC patients.</p><p><strong>Methods: </strong>This study retrospectively included 161 patients who underwent esophagectomy at Sichuan Cancer Hospital from July 2018 to February 2023. Pathological staging outcomes encompassed overall TNM staging, T and N staging, and tumor progressions (vascular invasion and perineural invasion). Radiomics features were extracted from segmented regions of tumors. A radiomic signature (Rad-signature) for each outcome was developed using a fivefold cross-validation least absolute shrinkage and selection operator (LASSO) regression model within the training cohort and subsequently validated in the test cohort for predictive accuracy.</p><p><strong>Results: </strong>Out of the 851 radiomics features extracted, two were selected to formulate the Rad-signature for each staging outcome. These signatures showed a significant correlation with their respective outcomes in both the training set and the testing set. Furthermore, the Rad-signature exhibited favorable predictive performance for advanced pTNM staging, advanced pT staging, vascular invasion and perineural invasion, with AUC of 0.721 [95%CI, 0.570-0.872], 0.900 [95%CI 0.805-0.995], 0.824 [0.686-0.961], and 0.737 [0.586-0.887], respectively. However, the predictive performance of the Rad-signature for pN staging is moderate (AUC = 0.693 [0.534-0.852]), indicating needs for additional data modalities.</p><p><strong>Conclusions: </strong>This study established a non-invasive preoperative radiomics model that demonstrated good predictive performance in determining the pTNM staging, pT staging, vascular invasion, and perineural invasion for EC patients. These results could inform personalized treatment strategies and improve outcomes for EC patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"298"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.","authors":"Yuanhang Han, Jiangtao Xie, Yuyang Wang, Xiaoxiao Liang, Yuanlong Xie","doi":"10.1186/s12885-025-13722-y","DOIUrl":"10.1186/s12885-025-13722-y","url":null,"abstract":"<p><strong>Background: </strong>Metastatic or recurrent bone sarcomas are often associated with an unfavorable prognosis, posing a formidable challenge in extending patients' survival. Currently, regorafenib has shown promise in treating metastatic and recurrent bone sarcomas. However, there is a lack of consensus on its efficacy and safety. This systematic review and meta-analysis aims to consolidate existing data to assess the efficacy and safety of regorafenib in bone sarcomas.</p><p><strong>Methods: </strong>A comprehensive search strategy utilizing MeSH terms and free-text keywords was employed to systematically search the Embase, PubMed, Web of Science, and Cochrane databases up to May 26, 2024. Randomized controlled trials investigating regorafenib monotherapy for metastatic or recurrent bone sarcomas were included. The primary outcomes of interest were progression-free survival (PFS), overall survival(OS) and adverse events (AEs).</p><p><strong>Results: </strong>We retrieved 335 articles and included 5 of them. Regorafenib significantly extended PFS-3 months and PFS-6 months in patients with metastatic or recurrent bone sarcomas compared to the control group, exhibiting a favorable odds ratio (OR) of 2.04 (95% CI: 1.21-2.86, P < 0.01) and 1.03 (95% CI: 0.08-1.99, P < 0.05), respectively. However, regorafenib did not improve OS at any observation point compared with the control group(P > 0.05), and the frequency of AEs was higher, with an odds ratio of 1.35 (95% CI: 0.63-2.07, P < 0.01).</p><p><strong>Conclusion: </strong>Regorafenib emerges as a promising therapeutic option for metastatic or recurrent bone sarcomas, demonstrating certain clinical benefits alongside manageable adverse reactions. Nevertheless, further research is warranted to refine the efficacy and safety profile of regorafenib, particularly in exploring safe dosage ranges or alternative treatment modalities.</p><p><strong>Registration number: </strong>CRD42024551705.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"302"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol.","authors":"T F Stoop, L W F Seelen, F R van 't Land, A C van der Hout, J C M Scheepens, M Ali, A M Stiggelbout, B M van der Kolk, B A Bonsing, D J Lips, D J A de Groot, E van Veldhuisen, E D Kerver, E R Manusama, F Daams, G Kazemier, G A Cirkel, G van Tienhoven, G A Patijn, H N Lelieveld-Rier, I H de Hingh, I E G van Hellemond, J H Wijsman, J I Erdmann, J S D Mieog, J de Vos-Geelen, J W B de Groot, K R D Lutchman, L J Mekenkamp, L W Kranenburg, L P M Beuk, M W Nijkamp, M den Dulk, M B Polée, M Y V Homs, M L Wumkes, M W J Stommel, O R Busch, R F de Wilde, R T Theijse, S A C Luelmo, S Festen, T L Bollen, U P Neumann, V E de Meijer, W A Draaisma, B Groot Koerkamp, I Q Molenaar, C L Wolfgang, M Del Chiaro, M G H Katz, T Hackert, J A C Rietjens, J W Wilmink, H C van Santvoort, C H J van Eijck, M G Besselink","doi":"10.1186/s12885-025-13554-w","DOIUrl":"10.1186/s12885-025-13554-w","url":null,"abstract":"<p><strong>Background: </strong>The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Netherlands, the nationwide resection rate for LAPC remains low at 8%. The PREOPANC-4 program aims for a nationwide implementation of the international multidisciplinary best-practice to improve patient outcome.</p><p><strong>Methods: </strong>Nationwide program implementing the international multidisciplinary best-practice for LAPC. In the training phase, multidisciplinary and surgical webinars are given by 4 international experts, leading to a clinical protocol, followed by surgical off-site and on-site proctoring sessions. In the implementation phase, the clinical protocol will be implemented in all centres, including a nationwide expert panel (2022-2024). Healthcare professionals will be trained in shared decision-making. Consecutive patients diagnosed with pathology-proven LAPC (i.e., arterial involvement > 90° and/or portomesenteric venous > 270° involvement or occlusion [DPCG criteria]) are eligible. Primary outcomes are median and 5-year OS from diagnosis, resection rate, in-hospital/30-day mortality and major morbidity (i.e., Clavien-Dindo grade ≥ IIIa), and radical resection (R0) rate. Secondary outcomes include quality of life, functioning, side effects, and patients' healthcare satisfaction in all included patients. Outcomes will be compared with patients with borderline resectable pancreatic cancer (BRPC) treated with neoadjuvant FOLFIRINOX in the PREOPANC-2 trial (EudraCT: 2017-002036-17) and a historical cohort of patients with LAPC from the PACAP registry (NCT03513705). The existing prospective LAPC Registry and PACAP PROMs (NCT03513705) will be used for data collection. In qualitative interviews, treatment preferences, values, and experiences of LAPC patients, their relatives, and healthcare professionals will be assessed for the development of shared decision-making supportive tools. It is hypothesized that the program will double the nationwide LAPC resection rate to 16% with major morbidity < 50% and mortality ≤ 5%, and OS following resection similar to that observed in patients with BRPC.</p><p><strong>Discussion: </strong>The PREOPANC-4 program aims to safely implement the international multidisciplinary best-practice for LAPC leading to benchmark outcomes for both short-term morbidity, mortality, and OS.</p><p><strong>Trial registration: </strong>PREOPANC-4 program was registered at ClinicalTrials.gov (NCT05524090) on September 1, 2022.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"299"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.","authors":"Na Yang, Xi Zhou, Yangmei Gong, Zhizhi Deng","doi":"10.1186/s12885-025-13461-0","DOIUrl":"10.1186/s12885-025-13461-0","url":null,"abstract":"<p><p>In this study, the influence of glycoproteomic changes, specifically MUC16, on NK cell-mediated immunotherapy response in ovarian cancer is explored. Analysis of glycoprotein data from the CPTAC database identified significant upregulation of MUC16 in ovarian cancer tissues, associated with tumor invasiveness and immune evasion. Experimental findings showed that MUC16 knockdown increased NK cell cytotoxicity, decreased invasiveness, and boosted NK cell activation, while MUC16 overexpression resulted in the opposite effects. In vivo experiments demonstrated that MUC16 knockdown suppressed tumor growth, enhanced NK cell infiltration, and bolstered NK cell activation, underscoring the potential of MUC16 as a target for novel immunotherapy approaches in ovarian cancer treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"294"},"PeriodicalIF":3.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}